Paul Michael Barr MD

PubMed

• Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia.
  Charles C Chu, Clare B Heffernan, Nydia C Jaimes-Delgadillo, Christine A Herne, Jennifer E Bruno
  Hemasphere. 2026-07-01
• Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plu...
  Paolo Ghia, Davide Rossi, Emmanuelle Ferrant, Fátima de la Cruz Vicente, Dai Maruyama
  Journal of Geriatric Oncology. 2026-07-01
• Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort Study.
  John Mariano, Myla Strawderman, Eric Snyder, Tina Faugh, Danielle S Wallace
  Journal of Adolescent and Young Adult Oncology. 2026-06-01

Journal Articles

• Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...  
  Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
• Recommendations for Clinical Trial Development in Follicular Lymphoma  
  Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM, J Natl Cancer Inst, 1/31/2016
• Prospective Clinicogenetic Risk Models To Predict Early Progression of Follicular Lymphoma after First-Line Immunochemotherapy  
  Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors ..., Blood, 1/25/2016

Books/Book Chapters

• Rare Lymphomas 
  Chapter: Adult Burkitt Lymphoma and Leukemia. 
  Page 171 - 194Gokbuget N, Barr PM, Friedberg JW, Hsi ED, Ott GEditors: Dreyling M.Springer-Verlag Berlin Heidelberg, New York2014
• Textbook of Uncommon Cancers 
  Chapter: Rare B Cell Lymphoproliferative Disorders. 
  Barr PM, Friedberg JWEditors: Sekkeres MA.Wiley-Blackwell, Oxford, EnglandEdition 4th,2012
• Adult Acute Lymphocytic Leukemia: Biology and Treatment 
  Chapter: Pharmacology of Acute Lymphoblastic Leukemia Therapy. 
  Barr PM, Creger RJ, Berger NAEditors: Advani A, Lazarus HM.Humana Press, New York, NY2010

Abstracts/Posters

• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibru... 
  2019 ASCO Annual Meeting - 6/1/2019
• Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

• Clinical evaluation and management of Burkitt Lymphoma 
  Barr PM, Friedberg JW, Clinical Decision Support in Hematology, 1st Edition
  1/1/2013
• Non-Hodgkin Lymphoma. 
  Barr PM and Fisher RI, Clinical Care Options in Practice (Govindan R, Kantarjian H.(eds)
  1/1/2009